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Transcriptional tissue specificity was engineered directly into Moloney Murine Leukaemia Virus (Mo-MLV)-derived retrovi-
ral vectors by replacing the viral enhancer in the 3* long terminal repeat (LTR) with two different lengths (2.5 kbp or 769
bp) of the murine tyrosinase promoter/enhancer. The hybrid tyrosinase-LTR was transferred to the proviral 5* LTR following
viral packaging and infection of target cell lines. Hybrid tyrosinase-LTR-driven IL-2 production was barely above background
levels in infected nonmelanoma cell lines containing intact provirus, whereas infected melanoma cell lines expressed high
levels of IL-2 and the larger tyrosinase promoter/enhancer fragment directed higher levels of transgene expression. By
replacing the viral enhancer with the tyrosinase promoter/enhancer sequences, promoter interference effects which we
have previously observed when the tyrosinase promoter was included as an internal promoter within a similar retroviral
vector were effectively abolished. Our data show that the hybrid tyrosinase-LTR behaves as a tightly regulated melanocytic-
specific regulatory element when embedded in an enhancer-deleted Mo-MLV LTR. The use of other heterologous cellular
promoter/enhancer elements in similar vectors should allow the development of simpler, targeted retroviral vectors for the
expression of genes in selected cell types and may eventually provide for the development of safer, more efficient vectors
for use in human gene therapy. q 1995 Academic Press, Inc.
Retroviral tropism is controlled at several different lev- for lymphoid cells which is determined in large part by
els including the transcriptional activity of the viral long the U3 enhancer sequences (6, 12).
terminal repeat (LTR) in the infected cell (1, 2). Many of It has been suggested that replacement of parts of the
the recombinant retroviral vectors which have been used U3 region of Mo-MLV by the corresponding U3 region
to infect human cells to date utilise a Moloney Murine of another virus may modify the activity of the resulting
Leukaemia Virus (Mo-MLV) LTR. Although such vectors chimaeric LTR, such that specific transcriptional tropisms
often include an internal promoter to direct expression can be introduced into retroviral vectors (11, 14, 15). We
of at least one of the vector-encoded genes (3), the LTR have been interested in the delivery of therapeutic genes
is often used to direct expression of another gene in the to tumour cells for the gene therapy of malignant mela-
infected cell. Transcription from MLV LTRs is dependent noma and have previously developed vectors which in-
upon the viral promoter/enhancer elements in the U3 corporate transcriptional regulatory elements to restrict
region of the 5* LTR (4, 5, 6) and, with a few exceptions expression of the therapeutic gene to melanoma cells.
(7), the U3 region of the LTR acts as a constitutive pro- Using 2.5 kbp, or as little as 769 bp, of the murine tyrosi-
moter/enhancer in many different cells, although certain nase promoter, we have previously shown that plasmid
viruses show preferential transcriptional tropisms (8, 9, (16, 17, 18) and retroviral (19, 20) vectors can be con-
10). The actual spectrum of the LTR’s activity is deter- structed in which cytokine or cytotoxic genes are prefer-
mined by the presence of a conserved, repeated domain entially expressed in melanoma cells. The retroviral vec-
upstream of the promoter which constitutes the viral en- tors used in these studies used the tyrosinase promoter
hancer (9, 10, 11, 12, 13, 14). For example, the AKR and as an internal promoter within a minigene construct (19).
SL3-3 murine leukaemia viruses have a preferred tropism However, we, and others, have observed that such con-
structs suffer from various drawbacks including promoter
interference, partial loss of tissue specificity from the
1 To whom correspondence and reprint requests should be ad- internal promoter, and reduced titres due to the inclusiondressed. Fax: 0171 9228216.
of relatively bulk minigenes often in the opposite orienta-2 Current address: 14 Chemin des Alux, 1228 Plan-les-ouates, Glaxo
Institute of Molecular Biology, Geneva, Switzerland. tion to the viral LTR (3, 19, 21, 22, 23).
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FIG. 1. Retroviral constructs and the generation of hybrid tyrosinase-LTR viral vectors. (A) pCDNeo which incorporates a deletion of the U3
enhancer in the 3* LTR. An internal SV40 early promoter directs expression of the Neo gene. (B) pCDNeo Tyr(2.5) and pCDNeo Tyr(.769) were
derived from pCDNeo by cloning 2.5-kbp or 769-bp fragments of the murine tyrosinase promoter/enhancer region (16) into the EcoRI and MluI
restriction sites in the polylinker of pCDNeo. (C) pCDNeo IL-2, pCDNeo IL-2 Tyr(2.5), and pCDNeo IL-2 Tyr(.769) were derived by cloning the murine
IL-2 gene into the XhoI site of pCDNeo, pCDNeo Tyr(2.5), and pCDNeo Tyr(.769), respectively. Full details of these constructs are available on
request.
In the first step to generate improved, melanoma-tar- in Fig. 1. The 3* LTR of pCDNeo has had the 72-bp repeat
enhancer element of the Mo-MLV LTR U3 region deletedgeted vectors, we reasoned that replacement of the Mo-
MLV viral enhancer in the LTR with the tyrosinase pro- between the PvuII and XbaI sites in the U3 region of the
3* LTR. In addition, the NheI site in the LTR has beenmoter/enhancer elements might generate a retroviral
vector in which gene expression from the LTR was re- replaced by a polylinker into which the tyrosinase en-
hancer/promoter region can be cloned. This enhancer-stricted to cells of melanocytic origin. Here, we describe
the production of two Mo-MLV-based vectors which ex- deleted LTR retains the viral U3 CCAAT (CAT box) and
AATAAAA (TATA box) elements. In addition, both of thepress a transgene from a chimaeric LTR in which the
viral enhancer has been removed and nonhomologous, tyrosinase promoter/enhancer elements retain the CAT
and TATA boxes of the tyrosinase promoter (24). We havecellular promoter/enhancer elements of the murine tyro-
sinase gene have been inserted into the U3 region of previously shown that these promoter fragments confer
tissue-specific expression to heterologous genes whenthe 3* LTR enhancer-deleted Mo-MLV vector, pCDNeo.
Cells infected by viral stocks derived from these vectors included in plasmids (16, 17) and as internal promoters
in retroviral vectors (19). Following reverse transcriptionexpressed the LTR-driven transgene in the expected tis-
sue-specific way. Thus, we have demonstrated that it is of these vectors, it would be predicted that the U3 region
of the 3* LTR of the plasmids would serve as the templatepossible to engineer tissue specificity into the U3 en-
hancer region of a viral LTR by incorporation of cellular from which the U3 regions of the 5* and 3* LTRs of the
resultant provirus would be derived (2, 25). Hence, thetranscriptional regulatory elements rather than simply by
exchanging homologous viral regions (14, 15). tyrosinase inserts in the 3* LTRs should be transferred
into the 5* LTR in infected cells. It is these hybrid 5* LTRsThe pCDNeo, pCDNeo Tyr(2.5), pCDNeo Tyr(.769),
pCDNeo IL-2, pCDNeo IL-2 Tyr(2.5), and pCDNeo IL-2 which would be expected to direct transcription of the
mRNA encoding the mIL-2 gene. When transfected intoTyr(.769) retroviral vectors were constructed as shown
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TABLE 1 ble to those produced by a selected population of B16
cells infected with pBabe Neo IL-2 in which the IL-2 geneRetroviral Titres from Pooled, G418r AM12 Cells Transfected
is driven by an intact Mo-MLV LTR (data not shown). Thiswith pCDNeo and Derivative Vectors
observation is consistent with our previous findings that
Virus titrea the 2.5-kbp promoter fragment serves as a more powerful
(G418r c.f.u./ml) promoter in melanoma cells than the shorter 769-bp frag-
ment, although both retain tissue specificity of expres-Target cell line
sion (16).
Viral construct B16 NIH3T3 In contrast, IL-2 production was barely higher than
background levels in the supernatants of nonmelanoma
pCDNeo 2700 6300 cell lines following infection with recombinant virus (Figs.
pCDNeo Tyr(2.5) 1300 3600
2D and 2E), indicating that the hybrid tyrosinase-LTR be-pCDNeo Tyr(.769) 1900 4600
haves as a tightly regulated melanocytic-specific regula-pCDNeo IL-2 Tyr(2.5) 1200 3100
pCDNeo IL-2 Tyr(.769) 1700 3800 tory element when embedded in an enhancer-deleted
pCDNeo IL-2 2800 6000 Mo-MLV LTR. This lack of IL-2 production was not due
to an inability of these lines to secrete IL-2 since wea Values shown are from one of three similar experiments. Viruses
have previously generated pooled populations of IL-2-were titred using a modification of the method described by Morling
secreting Colo26 and NIH3T3 cells using the pBabeNeoand Russell (41). Briefly, target cells were incubated with virus-con-
taining supernatants from the transfected producer cell lines in which IL-2 vector in which the IL-2 gene is driven by a fully
the calcium concentration had been raised to 5 mM, under which intact Mo-MLV LTR (19 and data not shown).
conditions a thin precipitate of calcium phosphate was visible. Four To exclude the possibility that lack of IL-2 expression
hours later the viral supernatants were removed, the cells were
from the nonmelanoma cell lines was due to re-washed, and 8 ml of normal growth medium was added to the plate.
arrangement of the viral genome, we used PCR andThe infected cells were grown for a further 72–96 hr before being split
into selection medium. Southern blotting to confirm the integrity of the proviral
structure in infected cells (Fig. 3). Primer pair P1/P6 will
detect a 2.8-kbp fragment including the 5* end of the 2.5-
kbp tyrosinase promoter fragment when it is inserted intoAM12 packaging cells, all the vector plasmids generated
retroviral vector stocks that were capable of transferring both the 5* and the 3* LTRs. Primer pair P3/P6 will detect
a 1-kbp fragment representing the 3* 769 bp of both thea functional Neo gene to target cells (Table 1).
The retroviral supernatants from the G418-resistant 2.5-kbp and the 769-bp tyrosinase promoter fragments
inserted into the viral LTRs. Primer pair P3/P5 will exclu-AM12 packaging lines were used to infect target cell
lines of melanocytic and nonmelanocytic lineage. B16.F1 sively amplify a 2.6-kbp fragment from proviruses in
which the tyrosinase promoter (both 2.5 kbp and 769 bp)and MeWo are melanoma cell lines of murine and human
origins, respectively; NIH3T3 is a murine fibroblast and is present in the 5* LTR and the IL-2 gene is correctly
inserted downstream within the vector as shown in Fig.Colo26 is a murine colorectal tumour line of epithelial
origin. Following infection, these target cells were split 3A. Taken together, these primers detected intact provi-
ruses of the predicted structure (Fig. 3A). However, thisinto selection medium (G418) and colonies were pooled.
Supernatants from these selected cells were assayed for PCR assay does not exclude the presence of rearranged
proviruses in the infected cells; therefore, Southern blotsthe presence of secreted IL-2 (Fig. 2).
As expected, AM12 cells transfected with pCDNeo IL- were performed to indicate the proportion of infected
cells in which integrated proviruses had rearranged. Ge-2, pCDNeo IL-2 Tyr(2.5), and pCDNeo IL-2 Tyr(.769) pro-
duced IL-2, and at equivalent levels since the expression nomic DNA from infected cell lines was digested with
EcoRI and KpnI to give proviral-specific band of 3.2 kbpof the IL-2 gene is driven by the intact Mo-MLV 5* LTR
in the retroviral plasmid (Fig. 2A). when hybridised with a virus-specific probe correspond-
ing to the Psi packaging signal (Fig. 3C). Standards wereFollowing infection of the two melanoma lines (B16
and MeWo), IL-2 was detected only from cells infected run using a B16 clone (clone 3) in which the pCDNeo IL-
2 provirus is present at single copy in order to quantitatewith pCDNeo IL-2 Tyr(2.5) and pCDNeo IL-2 Tyr(.769)
(Figs. 2B and 2C). IL-2 production from cells infected with the approximate copy number of the provirus in the in-
fected populations. Figure 3C shows that the infectedpCDNeo IL-2 was no higher than background level in
either line, indicating that the enhancer deletion of the populations contain proviruses at a copy number of ap-
proximately one. In addition, digestion with EcoRI alone3* LTR is efficiently transferred to the 5* LTR following
reverse transcription and greatly reduces transcription would be expected to generate a proviral fragment con-
taining the 5* LTR tyrosinase insertion and the body offrom the viral LTR. IL-2 production was significantly
greater in both B16 and MeWo cells infected with the the proviral vector (Fig. 3D). Any rearranged proviruses
would be represented by a smear indicating molecularpCDNeo IL-2 Tyr(2.5) vector than in cells infected with
pCDNeo IL-2 Tyr(.769), and these levels were compara- species of different molecular weights. Figure 3D demon-
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FIG. 2. Interleukin-2 production from cells transfected or infected with tyrosinase-LTR hybrid retroviral vectors. Cells (106) were seeded in normal
medium, and 48 hr later supernatant was harvested and filtered (0.2-mm Nalgene filter) and the cells were trypsinised and counted. The supernatant
was then assayed for IL-2 using a commercially available ELISA using antibody pairs obtained from Pharmingen. Construct numbers are as follows:
1, pCDNeo; 2, pCDNeo Tyr(2.5); 3, pCDNeo Tyr(.769); 4, pCDNeo IL-2; 5, pCDNeo IL-2 Tyr(2.5), 6, pCDNeo IL-2 Tyr(.769). (A) G418r AM12 producer
cells transfected with constructs 1–6. G418r (B) B16, (C) MeWo, (D) NIH3T3, and (E) Colo26 cells infected with recombinant virus from constructs
1– 6. Error bars represent standard deviations of the mean IL-2 production from triplicate samples.
strates that the predominant species of proviral DNA moter was included as an internal promoter within the
body of a retroviral vector (19). In those constructs, low,in the infected populations is that predicted for intact,
unrearranged provirus at an approximate copy number but significant, levels of expression were observed from
the tyrosinase promoter directing expression of the IL-2of one per cell, since no appreciable smearing is seen
even after long exposure times. Therefore, even when a gene in cells of nonmelanocytic lineages (such as
NIH3T3), presumably because of the influence of the viralpromoter/enhancer element of 2.5 kbp is transferred into
the 5* LTR, we did not observe large-scale re- enhancer on the tyrosinase promoter (21). In the studies
presented here, by deleting the viral enhancer and re-arrangements of the proviral structure either in infected
cell lines which did produce IL-2 (B16 and MeWo) or in placing it with the tyrosinase promoter/enhancer se-
quences, we have demonstrated that such interferencethose which did not (NIH3T3 or Colo26).
These results reported here represent an improvement effects can be abolished. Therefore, the transcriptional
restrictions imposed upon heterologous genes by theon our previous experiments in which the tyrosinase pro-
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FIG. 3. Integrity of proviral structure in infected cells. (A) High-molecular-weight DNA was prepared from retrovirally infected cells using the
Puregene kit (Flowgen Instruments Ltd., Sittingbourne, UK). One microgram of genomic DNA was used for each PCR reaction using 30 cycles (947,
1 min denaturation; 587, 1.5 min annealing; and 727, 3.5 min extension). In all experiments, a mock PCR (without added DNA) was performed to
exclude contamination. Location of primers P1, P6, P3, and P5 in the provirus in the genome of an infected cell are shown (details of primers
available on request). Sizes of amplified products using appropriate pairs of primers are shown. (B) Typical results of PCR assay using primer pairs
P1/P6, P6/P3, and P3/P5 on genomic DNA of NIH3T3 cells infected with retroviral vectors. Lane 1, pCDNeo; 2, pCDNeo Tyr(2.5); 3, pCDNeo Tyr(.769);
4, pCDNeo IL-2; 5, pCDNeo IL-2 Tyr(2.5); 6, pCDNeo IL-2 Tyr(.769); 7, pBabeNeo. Markers, lambda DNA digested with HindIII. (C) Genomic DNA
was prepared from infected cell lines as above. DNAs were digested with EcoRI/KpnI and hybridised with a virus-specific probe (Mo-MLV Psi
sequence). Genomic DNAs from mixtures of parental B16 cells admixed with different numbers of cells of clone 3, a B16 clone harbouring a single
copy of pCDNeo IL-2, were used as a copy number reference control. EcoRI/KpnI-digested DNAs from lane 1, 105 parental B16 cells; lanes 2–5,
105 cells containing clone 3 cells at copy numbers 1, 0.1, 0.01, and 0.001; lanes 6–8, 105 B16 cells infected with pCDNeo IL-2, pCDNeo IL-2 Tyr(.769),
and pCDNeo IL-2 Tyr(2.5). (D) Lanes 9–11, EcoRI-digested DNAs from 105 B16 cells infected with pCDNeo IL-2, pCDNeo IL-2 Tyr(.769), and pCDNeo
IL-2 Tyr(2.5), respectively. Similar results were obtained using DNA from populations of infected NIH3T3 cells.
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tissue-specific tyrosinase promoter, which have been geted, stable, and high-level expression of transgenes
in specific cell types.well documented in plasmid expression vectors (16, 24,
26), can also be preserved well in the context of retroviral
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